Crohn's Disease and Colitis Trial, Recruiting NCT06523647 Sponsor: Kazakhstan Scientific Society for Study of intestine diseases Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Recruiting

NCT06523647
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who were first prescribed the medication Ustekinumab between January 1 and December 31, 2024
  • People who have given written consent to take part in the study

Who may not be able to join:

  • People with a serious active infection, such as active tuberculosis or active viral hepatitis
  • People who are pregnant or breastfeeding
  • People with a history of significant mental health conditions that, in the opinion of the investigator, could interfere with following the study procedures or medication schedule
  • People who have been diagnosed with ulcerative colitis (a type of inflammatory bowel disease)
  • People who have had, or currently have, a cancerous condition affecting the digestive system
  • People with severe, poorly controlled long-term conditions affecting the liver, kidneys, heart and blood vessels, blood vessel inflammation, or diabetes
  • People who have had problems with alcohol or drug misuse in the year before the study started (as reported by the patient)
  • People who are currently taking part in another interventional clinical trial (a study where a treatment or procedure is being tested)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +7 707 413 8263

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Kazakhstan Scientific Society for Study of intestine diseases
Registry
ClinicalTrials.gov
Start date
27 June 2023
Est. completion
1 December 2025

Where this trial is recruiting

🇰🇿 Kazakhstan

Primary endpoints

The proportion of patients with a reduced level of disease activity by 30% or more according to the Crohn's Disease Activity Index

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov